QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
NASDAQ:CVAC

CureVac (CVAC) Stock Price, News & Analysis

$3.07
+0.02 (+0.66%)
(As of 12:51 PM ET)
Today's Range
$3.05
$3.19
50-Day Range
$2.94
$3.80
52-Week Range
$2.76
$12.36
Volume
216,886 shs
Average Volume
801,274 shs
Market Capitalization
$687.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

CureVac MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
388.6% Upside
$15.00 Price Target
Short Interest
Bearish
5.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
0.67mentions of CureVac in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.42 out of 5 stars

Medical Sector

314th out of 939 stocks

Pharmaceutical Preparations Industry

139th out of 433 stocks

CVAC stock logo

About CureVac Stock (NASDAQ:CVAC)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CVAC Stock Price History

CVAC Stock News Headlines

CVAC Oct 2024 7.500 call
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
CureVac: No Momentum In Sight
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
CureVac price target lowered to $6.40 from $8 at BofA
CureVac stock down 43.5% in premarket trading
Curevac Share Price (1CVAC.MI)
CureVac: Failing To Live Up To Its Initial Hype
See More Headlines
Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/29/2020
Today
3/28/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CVAC
Employees
1,049
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$24.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+391.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$72.33 million
Book Value
$2.88 per share

Miscellaneous

Free Float
N/A
Market Cap
$682.71 million
Optionable
Optionable
Beta
2.53
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Pierre Kemula B.Sc. (Age 49)
    MD, CFO & Member of Management Board
    Comp: $600k
  • Dr. Malte Greune Ph.D. (Age 59)
    COO, Member of Management Board & MD
    Comp: $466.62k
  • Dr. Ulrike Gnad-Vogt M.D. (Age 51)
    Ph.D., Senior VP & Area Head of Oncology
    Comp: $383.11k
  • Dr. Alexander Zehnder M.B.A. (Age 54)
    M.D., CEO, MD & Member of Management Board
  • Dr. Myriam Mendila M.D. (Age 58)
    Chief Development Officer, MD & Member of the Management Board
  • Dr. Sarah Fakih
    Vice President Corporate Communications & Investor Relations
  • Mr. Marco Rau L.L.M.
    Ph.D., General Counsel
  • Mr. Thorsten Schuller
    Head of Corporate Communications
  • Slavica Stevanovic-Heck
    Head of Human Resources
  • Dr. Patrick Baumhof
    Senior Vice President of Technology

CVAC Stock Analysis - Frequently Asked Questions

Should I buy or sell CureVac stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CVAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares.
View CVAC analyst ratings
or view top-rated stocks.

What is CureVac's stock price target for 2024?

2 Wall Street analysts have issued 1-year price targets for CureVac's shares. Their CVAC share price targets range from $8.00 to $24.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 388.6% from the stock's current price.
View analysts price targets for CVAC
or view top-rated stocks among Wall Street analysts.

How have CVAC shares performed in 2024?

CureVac's stock was trading at $4.21 at the beginning of the year. Since then, CVAC stock has decreased by 27.1% and is now trading at $3.07.
View the best growth stocks for 2024 here
.

Are investors shorting CureVac?

CureVac saw a increase in short interest in March. As of March 15th, there was short interest totaling 4,860,000 shares, an increase of 10.7% from the February 29th total of 4,390,000 shares. Based on an average daily volume of 876,200 shares, the short-interest ratio is currently 5.5 days. Approximately 5.3% of the company's shares are short sold.
View CureVac's Short Interest
.

When is CureVac's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our CVAC earnings forecast
.

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) announced its earnings results on Sunday, November, 29th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($54.37) by $54.13.

What ETFs hold CureVac's stock?

ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) and Morningstar US Small Growth (MSGR).ProShares Nanotechnology ETF (TINY).

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO).

When did CureVac IPO?

CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.

Who are CureVac's major shareholders?

CureVac's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.04%), Price T Rowe Associates Inc. MD (1.04%), Platinum Investment Management Ltd. (0.22%), Goldman Sachs Group Inc. (0.17%), Goldman Sachs Group Inc. (0.17%) and Norges Bank (0.14%).

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVAC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners